About Sevodyne

For more information about Sevodyne, please see the prescribing information.

Welcome to

Sevodyne (buprenorphine) transdermal patches are indicated for the treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.1

Available as:

  • Transdermal patch 5 microgram/hr

  • Transdermal patch 10 microgram/hr

  • Transdermal patch 15 microgram/hr

  • Transdermal patch 20 microgram/hr

Sevodyne transdermal patches are bioequivalent to Norspan® (buprenorphine) (Mundipharma GmbH, Germany)/BuTrans® (buprenorphine) (Napp Pharmaceuticals Ltd, UK) buprenorphine transdermal patches.2

Sevodyne could offer significant cost savings to your practice and integrated care system/board (ICS/B).3/4*

Buprenorphine 5 microgram/hr, 10 microgram/hr, 15 microgram/hr and 20 microgram/hr transdermal patches are on the UK Drug Tariffs.3

In addition with Sevodyne you can get:

  • Price guaranteed**

*Based on 69% saving on the cost of buprenorphine transdermal patches in the UK Drug Tariffs. Savings calculated from 2021 spend of 132 Healthboards/CCGs switching their generic and originator brand 5, 10, 15 and 20mcg buprenorphine transdermal patch prescriptions to Sevodyne. **No change in price subject to no material change to the products or of the UK Drug Tariffs until the 2024 PPRS review.
References: 1) Sevodyne SmPCs. 2) Data on file, 1010067149 v5.0 September 2021. 3) Nov 2022 UK Drug Tariffs. 4) Insypher Data :GPPLPD Date Range: May-22 -Jul-2210100831045 v 8.0 October 2022
Adverse events should be reported. Reporting forms and information can be found at:

Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148.


More products available
in this range:
Click to view their
individual websites